IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Immunocore Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.84+0.44 (+1.50%)
Close on Oct 19, 2026
- Market cap
- $1.52B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Immunocore Holdings plc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from sale of therapies, net | $430.78M | $412.81M | $400.02M | $379.59M | $356.15M | $333.53M | $309.99M | – | – | – | – | 100.0% | +21.0% |
| Product revenue, net | – | – | – | – | – | – | – | $293.53M | $275.91M | $257.50M | $238.74M | – | – |
| Collaboration revenue | – | – | $0 | $0 | $0 | $53.00K | $213.00K | $2.78M | $5.00M | $7.78M | $10.69M | – | – |
By region
From the segment and revenue-disaggregation notes of Immunocore's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.